Fresh Start, page-44

https://endpts.com/in-reversal-sarepta-to-face-fdas-panel-of-outside-experts-on-duchenne-gene-therapy/?u=9072b1fe-e439-4432-ace6-17b4dc5ff6e8&s=email&c=ead60ced-5061a111-c4a58490&utm_medium=email&utm_campaign=382%20-%20Amgen%20trims%20headcount%20again%20Surprise%20court%20order%20keeps%20IP%20dispute%20alive%20against%20Moderna%20Basic&utm_content=382%20-%20Amgen%20trims%20headcount%20again%20Surprise%20court%20order%20keeps%20IP%20dispute%20alive%20against%20Moderna%20Basic+CID_7ea062ca2b04f6cdf8797b4c3e2e8a11&utm_source=ENDPOINTS%20emails&utm_term=In%20reversal%20Sarepta%20to%20face%20FDAs%20panel%20of%20outside%20experts%20on%20Duchenne%20gene%20therapy

The Sarepta approval is not a done deal it seems.